Neoadjuvant/adjuvant therapy for liver resection and transplantation

B. K P Goh, C. B. Rosen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].

Original languageEnglish (US)
Title of host publicationHilar Cholangiocarcinoma
PublisherSpringer Netherlands
Pages281-289
Number of pages9
ISBN (Electronic)9789400764736
ISBN (Print)9400764723, 9789400764729
DOIs
StatePublished - Jan 1 2013

Fingerprint

Klatskin Tumor
Neoadjuvant Therapy
Liver Transplantation
Recurrence
Survival
Cholangiocarcinoma
Liver Failure
Sepsis
Transplantation
Research Personnel
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Goh, B. K. P., & Rosen, C. B. (2013). Neoadjuvant/adjuvant therapy for liver resection and transplantation. In Hilar Cholangiocarcinoma (pp. 281-289). Springer Netherlands. https://doi.org/10.1007/978-94-007-6473-6_26

Neoadjuvant/adjuvant therapy for liver resection and transplantation. / Goh, B. K P; Rosen, C. B.

Hilar Cholangiocarcinoma. Springer Netherlands, 2013. p. 281-289.

Research output: Chapter in Book/Report/Conference proceedingChapter

Goh, BKP & Rosen, CB 2013, Neoadjuvant/adjuvant therapy for liver resection and transplantation. in Hilar Cholangiocarcinoma. Springer Netherlands, pp. 281-289. https://doi.org/10.1007/978-94-007-6473-6_26
Goh BKP, Rosen CB. Neoadjuvant/adjuvant therapy for liver resection and transplantation. In Hilar Cholangiocarcinoma. Springer Netherlands. 2013. p. 281-289 https://doi.org/10.1007/978-94-007-6473-6_26
Goh, B. K P ; Rosen, C. B. / Neoadjuvant/adjuvant therapy for liver resection and transplantation. Hilar Cholangiocarcinoma. Springer Netherlands, 2013. pp. 281-289
@inbook{f2c8a7823b19435291ff58b84d6eac17,
title = "Neoadjuvant/adjuvant therapy for liver resection and transplantation",
abstract = "Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 {\%} to 52 {\%} [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 {\%} of patients develop distant metastases before locoregional recurrence [7].",
author = "Goh, {B. K P} and Rosen, {C. B.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-94-007-6473-6_26",
language = "English (US)",
isbn = "9400764723",
pages = "281--289",
booktitle = "Hilar Cholangiocarcinoma",
publisher = "Springer Netherlands",
address = "Netherlands",

}

TY - CHAP

T1 - Neoadjuvant/adjuvant therapy for liver resection and transplantation

AU - Goh, B. K P

AU - Rosen, C. B.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].

AB - Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].

UR - http://www.scopus.com/inward/record.url?scp=84931360760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931360760&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6473-6_26

DO - 10.1007/978-94-007-6473-6_26

M3 - Chapter

AN - SCOPUS:84931360760

SN - 9400764723

SN - 9789400764729

SP - 281

EP - 289

BT - Hilar Cholangiocarcinoma

PB - Springer Netherlands

ER -